Evaluation of safety following Immune Tolerance Induction treatment with turoctocog alfa in patients with haemophilia A following inhibitor development in NN7170-4213 trial

Registry ID

EUCTR2016-003821-40

Source registry

EUCTR

Status

Completed

Phase

PHASE3

Sponsor

Novo Nordisk A/S

Start date

2017-01-11

Completion date

2019-06-19

Last update

2026-08-16

Conditions

• Haemophilia A

Summary

To evaluate safety of immune tolerance induction treatment with turoctocog alfa in patients who have developed neutralising antibodies against factor VIII after exposure to subcutaneous turoctocog alfa pegol during participation in NN7170-4213

Locations

• , , Austria
• , , UK
• , , Bulgarian Drug Agency
• , , Germany

Related clinical trials

• Prevention of bleeding in haemophilia A by prophylactic treatment with Nuwiq®
• A Research Study Looking at How Different Doses of Study Medicine (Inno8) Work in the Body of People With Haemophilia A
• Study of Surgical Practices in Hemophilia A Patients Treated With Efanesoctocog Alfa (Altuvoct®)
• A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia A
• Post-Marketing Surveillance (All Case Surveillance) on Treatment With Alhemo® in Patients With Haemophilia A or Haemophilia B With Inhibitors
• Efficacy, Safety & Utilisation of Nuwiq, Octanate and Wilate in Previously Untreated & Minimally Treated Haemophilia A Patients

View on source registry